FDA Approves Tascenso ODT® (fingolimod), similar to Gilenya, for Relapsing MS
February 21, 2023 The U.S. Food and Drug Administration recently approved Tascenso ODT® (fingolimod, Cycle Pharmaceuticals) as an orally disintegrating tablet…
Gauging MS Disease Activity Through Octave’s MSDA Test
Feb 24, 2023 Taylor Gonyou, DO The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on…
Stuart Schlossman
What Causes Racial Disparities With Multiple Sclerosis?
And now to what we don’t know: More research is needed to determine if these differences are because of biological…
Stuart Schlossman
How Multiple Sclerosis Impacts Hispanic Americans
Latinx patients also have stark differences in MS from white patients—one 2021 study found that Hispanic Americans with MS…
Stuart Schlossman
How Multiple Sclerosis Impacts African Americans
Source Click to Subscribe for the MS Beacon eNewsletter, resources and MS educational events Visit our MS Learning Channel…
Stuart Schlossman
A Multicultural Guide to Managing Multiple Sclerosis
Race and ethnicity add unique challenges to living with this disease. @HealthCentral takes a closer look. Written by Erin Boyle …
Stuart Schlossman
The Focus of MS Care / Living Well with MS – Presented by: Lynn Stazzone, A.,N.P.,M.S. – Brigham Multiple Sclerosis Center
Shared Decision Making + MS Fatigue, Cognition, Depression and More Please CLICK…
Stuart Schlossman
Improve Your MS by Making MS Boring – Presented by Aaron Boster, MD
Watch Listen Learn then please Share with others so they too can learn more about MS Visit our MS…
Stuart Schlossman
• Learning about Visual Disturbances in MS
Event date: August 27th / Published Date: September 21, 2022 Listen with Dr. Jonathan Calkwood’s In-Depth discussion on Topics: •…
Stuart Schlossman
Multiple Sclerosis Prognosis and Life Expectancy
Last updated May 5, 2022, by Marisa Wexler, MS ✅ Fact-checked by Ines Martins, PhD Multiple sclerosis (MS) is a neurological…
Stuart Schlossman
